147 related articles for article (PubMed ID: 36422807)
1. Economic Impact of Transformation to Acute Myeloid Leukemia Among Actively Managed Patients with Higher-Risk Myelodysplastic Syndromes in the United States.
Kota V; Ogbonnaya A; Farrelly E; Schroader BK; Raju A; Kristo F; Dalal M
Adv Ther; 2023 Apr; 40(4):1655-1669. PubMed ID: 36422807
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.
Kota V; Ogbonnaya A; Farrelly E; Schroader BK; Raju A; Kristo F; Dalal M
Future Oncol; 2022 Nov; 18(36):4017-4029. PubMed ID: 36622291
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
[TBL] [Abstract][Full Text] [Related]
4. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
[TBL] [Abstract][Full Text] [Related]
5. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis.
Marsà A; Ascanio M; Diaz-García J; Darbà J
J Med Econ; 2020 Dec; 23(12):1477-1484. PubMed ID: 33084440
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
Hagiwara M; Sharma A; Chung KC; Delea TE
J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
9. Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes.
Cheng WY; Satija A; Cheung HC; Hill K; Wert T; Laliberté F; Lefebvre P
Hematology; 2021 Dec; 26(1):261-270. PubMed ID: 33631084
[TBL] [Abstract][Full Text] [Related]
10. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
[TBL] [Abstract][Full Text] [Related]
11. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
12. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
14. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
Cancer; 2010 Nov; 116(22):5279-89. PubMed ID: 20665502
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.
Wang R; Zeidan AM; Yu JB; Soulos PR; Davidoff AJ; Gore SD; Huntington SF; Gross CP; Ma X
Prostate; 2017 Apr; 77(5):437-445. PubMed ID: 27868212
[TBL] [Abstract][Full Text] [Related]
16. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
[TBL] [Abstract][Full Text] [Related]
17. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.
Goldberg SL; Chen E; Sasane M; Paley C; Guo A; Laouri M
Transfusion; 2012 Oct; 52(10):2131-8. PubMed ID: 22486790
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
Khan N; Patel D; Trivedi C; Kavani H; Pernes T; Medvedeva E; Lewis J; Xie D; Yang YX
Am J Gastroenterol; 2021 Apr; 116(4):741-747. PubMed ID: 33982944
[TBL] [Abstract][Full Text] [Related]
19. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
[TBL] [Abstract][Full Text] [Related]
20. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]